Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to the commercial launch of DIFICID in Canada, Optimer's ability to quickly provide DIFICID to physicians and patients in Canada, and expected trends in the incidence of CDI. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to commercialize DIFICID in Canada, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, the ability of Optimer to adequately prepare for the launch of DIFICID in Canada, including its ability to hire, maintain and manage a sales force in Canada, the development of alternative treatments for or means of preventing CDI, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage and other risks detailed in Optimer's filings with the Securities and Exchange Commission
Optimer's DIFICID® (fidaxomicin) Tablets Approved By Health Canada For The Treatment Of Clostridium Difficile Infection And Now Available To Canadian Patients
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.